Fifteen Years of LIFE (Losartan Intervention for Endpoint Reduction in Hypertension)-Lessons Learned for Losartan: An "old Dog Playing Good Tricks"

Overview

Journal J Clin Hypertens (Greenwich)

Specialty Cardiology & Vascular Diseases

Date 2018 Jun 17

PMID 29907995

Citations 4

Authors

Niki Katsiki

Konstantinos Tsioufis

Dilek Ural

Massimo Volpe

Affiliations

Soon will be listed here.

Abstract

There is an unmet need to prevent cardiovascular disease and chronic kidney disease development and progression worldwide. Losartan, the first angiotensin receptor blocker, was shown to exert significant cardioprotective and renoprotective effects in the LIFE (Losartan Intervention for Endpoint Reduction in Hypertension) and RENAAL (Reduction of Endpoints in NIDDM With the Angiotensin II Antagonist Losartan) trials. Losartan significantly prevented stroke and decreased serum uric acid levels and the rates of new-onset diabetes mellitus and atrial fibrillation. The present review discusses the LIFE (and its subanalyses) and RENAAL trials and the translation of their results to clinical practice. The place of losartan in the current guidelines for hypertension management is also discussed. Losartan still represents an efficacious, safe, and cost-effective therapeutic option in patients with hypertension who have left ventricular hypertrophy. Losartan is a useful antihypertensive agent for stroke prevention and in the management of patients with chronic kidney disease, atrial fibrillation, diabetes mellitus, albuminuria, and hyperuricemia.

Citing Articles

Drug-Induced Hypouricemia.

Ben Salem C, Agrebi M, Sahnoun D, Fathallah N, Hmouda H Drug Saf. 2024; 48(2):129-142.

PMID: 39289314 DOI: 10.1007/s40264-024-01485-7.

An overview of pyridazin-3(2)-one: a core for developing bioactive agents targeting cardiovascular diseases and cancer.

Abd-Rabo Z, Serry A, George R Future Med Chem. 2024; 16(16):1685-1703.

PMID: 39105606 PMC: 11370926. DOI: 10.1080/17568919.2024.2379234.

Effects of the DASH diet and losartan on serum urate among adults with hypertension: Results of a randomized trial.

Castilla-Ojo N, Turkson-Ocran R, Conlin P, Appel L, Miller 3rd E, Juraschek S J Clin Hypertens (Greenwich). 2023; 25(10):915-922.

PMID: 37695134 PMC: 10560966. DOI: 10.1111/jch.14721.

Fifteen years of LIFE (Losartan Intervention for Endpoint Reduction in Hypertension)-Lessons learned for losartan: An "old dog playing good tricks".

Katsiki N, Tsioufis K, Ural D, Volpe M J Clin Hypertens (Greenwich). 2018; .

PMID: 29907995 PMC: 8030909. DOI: 10.1111/jch.13325.

References

Tocci G, Paneni F, Palano F, Sciarretta S, Ferrucci A, Kurtz T . Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and diabetes: a meta-analysis of placebo-controlled clinical trials. Am J Hypertens. 2011; 24(5):582-90. DOI: 10.1038/ajh.2011.8. View

Katsiki N, Mikhailidis D . Hyperuricaemia in cardiovascular diseases: a passive or an active player?. Med Princ Pract. 2015; 24(3):269-70. PMC: 5588224. DOI: 10.1159/000381398. View

Dahlof B, Devereux R, Kjeldsen S, Julius S, Beevers G, de Faire U . Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002; 359(9311):995-1003. DOI: 10.1016/S0140-6736(02)08089-3. View

Kjeldsen S, Devereux R, Hille D, Lyle P, Dahlof B, Julius S . Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint reduction in hypertension study. Blood Press. 2009; 18(6):348-61. DOI: 10.3109/08037050903460590. View

Jonsson B, Carides G, Burke T, Dasbach E, Lindholm L, Dahlof B . Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial. J Hypertens. 2005; 23(7):1425-31. DOI: 10.1097/01.hjh.0000173527.73179.f5. View

Lindholm L, Ibsen H, Dahlof B, Devereux R, Beevers G, de Faire U . Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002; 359(9311):1004-10. DOI: 10.1016/S0140-6736(02)08090-X. View

Hill N, Fatoba S, Oke J, Hirst J, OCallaghan C, Lasserson D . Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis. PLoS One. 2016; 11(7):e0158765. PMC: 4934905. DOI: 10.1371/journal.pone.0158765. View

Gerdts E, Okin P, Omvik P, Wachtell K, Dahlof B, Hildebrandt P . Impact of diabetes on treatment-induced changes in left ventricular structure and function in hypertensive patients with left ventricular hypertrophy. The LIFE study. Nutr Metab Cardiovasc Dis. 2009; 19(5):306-12. DOI: 10.1016/j.numecd.2008.12.009. View

Katsiki N, Tsioufis K, Ural D, Volpe M . Fifteen years of LIFE (Losartan Intervention for Endpoint Reduction in Hypertension)-Lessons learned for losartan: An "old dog playing good tricks". J Clin Hypertens (Greenwich). 2018; . PMC: 8030909. DOI: 10.1111/jch.13325. View

10.

Volpe M, Junren Z, Maxwell T, Rodriguez A, Gamboa R, Gomez-Fernandez P . Comparison of the blood pressure-lowering effects and tolerability of Losartan- and Amlodipine-based regimens in patients with isolated systolic hypertension. Clin Ther. 2003; 25(5):1469-89. DOI: 10.1016/s0149-2918(03)80133-9. View

11.

Axelsson A, Iversen K, Vejlstrup N, Ho C, Havndrup O, Kofoed K . Functional effects of losartan in hypertrophic cardiomyopathy-a randomised clinical trial. Heart. 2015; 102(4):285-91. DOI: 10.1136/heartjnl-2015-308343. View

12.

Carr A, Kowey P, Devereux R, Brenner B, Dahlof B, Ibsen H . Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies. Am J Cardiol. 2005; 96(11):1530-6. DOI: 10.1016/j.amjcard.2005.07.061. View

13.

Roth G, Johnson C, Abajobir A, Abd-Allah F, Abera S, Abyu G . Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. J Am Coll Cardiol. 2017; 70(1):1-25. PMC: 5491406. DOI: 10.1016/j.jacc.2017.04.052. View

14.

Athyros V, Katsiki N, Karagiannis A, Mikhailidis D . Editorial: should chronic kidney disease be considered as a coronary heart disease equivalent?. Curr Vasc Pharmacol. 2012; 10(3):374-7. DOI: 10.2174/157016112799959422. View

15.

Fossum E, Olsen M, Hoieggen A, Wachtell K, Reims H, Kjeldsen S . Long-term effects of a losartan- compared with an atenolol-based treatment regimen on carotid artery plaque development in hypertensive patients with left ventricular hypertrophy: ICARUS, a LIFE substudy. J Clin Hypertens (Greenwich). 2006; 8(3):169-73. PMC: 8109329. DOI: 10.1111/j.1524-6175.2006.04838.x. View

16.

Borghi C, Rossi F . Role of the Renin-Angiotensin-Aldosterone System and Its Pharmacological Inhibitors in Cardiovascular Diseases: Complex and Critical Issues. High Blood Press Cardiovasc Prev. 2015; 22(4):429-44. DOI: 10.1007/s40292-015-0120-5. View

17.

Volpe M, Agabiti Rosei E, Ambrosioni E, Leonetti G, Trimarco B, Mancia G . Reduction in estimated stroke risk associated with practice-based stroke-risk assessment and awareness in a large, representative population of hypertensive patients: results from the ForLife study in Italy. J Hypertens. 2007; 25(12):2390-7. DOI: 10.1097/HJH.0b013e3282efc5a2. View

18.

Devereux R, Palmieri V, Liu J, Wachtell K, Bella J, Boman K . Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study. J Hypertens. 2002; 20(7):1445-50. DOI: 10.1097/00004872-200207000-00033. View

19.

Miao Y, Ottenbros S, Laverman G, Brenner B, Cooper M, Parving H . Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension. 2011; 58(1):2-7. DOI: 10.1161/HYPERTENSIONAHA.111.171488. View

20.

Okin P, Devereux R, Gerdts E, Snapinn S, Harris K, Jern S . Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study. Circulation. 2006; 113(12):1588-96. DOI: 10.1161/CIRCULATIONAHA.105.574822. View